StockTitan

@stocktitan.net

3 weeks ago

Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results Apyx Medical (NASDAQ:APYX) reported Q4 2025 total revenue of $19.2M and full-year 2025 revenue of $52.8M, driven by a commercial launch of the AYON Body Contouring System in September 2025. Surgical Aesthetics revenue rose 38.1% in Q4 and 17.4% for FY2025. Q4 adjusted EBITDA was positive at $0.7M; FY2025 adjusted EBITDA loss narrowed to $3.8M. The company ended 2025 with $31.7M cash and expects FY2026 revenue of $57.5M–$58.5M and operating expenses under $45.0M. A 510(k) submission for AYON power liposuction is anticipated to be cleared mid-2026.

#APYX Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/APYX/apyx-medical-c...

サードニュース@相互フォロー100%

@new3rd.bsky.social

1 month ago

アライドアーキテクツが新型ステーブルコイン「APYX」プロジェクトに出資 アライドアーキテクツ株式会社は、新しい利回り型ステーブルコイン「APYX」プロジェクトに投資を行いました。透明性と安定性を兼ね備えたこのプロジェクトの詳細をご紹介します。

アライドアーキテクツが新型ステーブルコイン「APYX」プロジェクトに出資 #東京都 #渋谷区 #アライドアーキテクツ #ステーブルコイン #APYX

アライドアーキテクツ株式会社は、新しい利回り型ステーブルコイン「APYX」プロジェクトに投資を行いました。透明性と安定性を兼ね備えたこのプロジェクトの詳細をご紹介します。

StockTitan

@stocktitan.net

2 months ago

New body contouring device helps drive 51% jump in U.S. sales Preliminary 2025 results show $52.7-$52.9M revenue, driven by 17% growth in Surgical Aesthetics and a 21% OEM decline ahead of March results.

#APYX Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

4 months ago

Apyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea Apyx Medical (Nasdaq: APYX) announced MFDS approval and the commercial launch of the Apyx One console and single-use handpieces for cosmetic surgical procedures in South Korea.The company plans to begin shipping to fill initial orders starting in Q4 2025. Apyx One combines Renuvion technology with monopolar and bipolar energy and features adaptive touch screens, procedural presets, energy quantification, and an advanced gas-monitoring system.Management cited South Korea’s cosmetic surgery market estimate of $1.7 billion in 2024 and a projected increase to $3.9 billion by 2033, and noted increased demand tied to GLP-1 weight-loss drug use and subsequent body-contouring needs.

#APYX Apyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

4 months ago

Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced

#APYX Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

4 months ago

Apyx Medical Corporation Announces Proposed Public Offering of Common Stock Apyx Medical (Nasdaq: APYX) announced on November 17, 2025 that it has commenced a proposed underwritten public offering of common stock or common stock equivalents, subject to market conditions.Lucid Capital Markets is sole book-running manager. The offering will be made from a shelf registration on Form S-3 (File No. 333-268532) declared effective December 2, 2022; a preliminary prospectus supplement and prospectus will be filed with the SEC and posted at www.sec.gov when available. The company cautioned there is no assurance the offering will be completed on the anticipated terms.Company products include Renuvion, AYON Body Contouring System (FDA-cleared), and J-Plasma, supported by more than 90 clinical documents.

#APYX Apyx Medical Corporation Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

4 months ago

#APYX Apyx Medical Corporation Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

5 months ago

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 Apyx Medical (NASDAQ: APYX) announced it will release its third quarter fiscal 2025 financial results before markets open on Thursday, November 6, 2025.Management will host a conference call at 8:00 a.m. Eastern Time on November 6 to discuss results and conduct a Q&A. Dial-in numbers are 800-717-1738 (U.S.) or 646-307-1865 (international) with access code 73607. A live webcast will be available and archived in the company’s Investor Relations section.Contact for investors is Jeremy Feffer at LifeSci Advisors (212-915-2568; jfeffer@lifesciadvisors.com). The company sells helium plasma and RF products under the Renuvion, AYON Body Contouring System, and J-Plasma brands, supported by more than 90 clinical publications.

#APYX Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

5 months ago

Apyx Medical Corporation Submits FDA 510(k) for Device Label Expansion of AYON Body Contouring System™ for Power Liposuction Apyx Medical (NASDAQ: APYX) announced on October 13, 2025 that it submitted a new FDA 510(k) premarket notification to expand the label of the AYON Body Contouring System to include power liposuction.The company began a nationwide commercial launch of AYON in September 2025 and said that, if cleared, the power liposuction function could be activated in systems already installed at U.S. surgical centers.A virtual key opinion leader event on October 14, 2025 will discuss the commercial launch.

#APYX Apyx Medical Corporation Submits FDA 510(k) for Device Label Expansion of AYON Body Contouring System™ for Power Liposuction

www.stocktitan.net/news/APYX/apyx-medical-c...

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Small-cap stocks with improving money flow, Wed Sept 24th - #WALD #VCIC #TNYA #SDST #QURE #PEPG #LINK #HOND #IAS #GNSS #COHU #APYX #OPAD #BKKT - More: crystalequityresearch.com/leading-indi... - #smallcap

StockTitan

@stocktitan.net

7 months ago

Apyx Medical Earnings: Revenue Guidance Jumps to $52M as New Body Contouring System Exceeds Launch Expectations Apyx boosts 2025 revenue outlook to $52M following strong AYON system pre-sales and Renuvion China launch. See how GLP-1 patients drive growth potential.

#APYX Apyx Medical Corporation Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

8 months ago

Apyx Medical Corporation Announces Launch of Renuvion® in China Apyx Medical Corporation (NASDAQ:APYX) has announced the launch of its Renuvion® technology in China, marking a significant expansion into one of the world's largest healthcare markets. The company has entered into a distribution agreement with GlamMoon Medical Technology, a division of BeauCare Clinics Investment Co., Ltd. (BCC), following initial market clearance from China's National Medical Products Administration.The partnership with BCC, which operates over 60 medical aesthetics hospitals and clinics across 15 Chinese cities, positions Renuvion for significant market penetration. Early clinical interest and completed procedures indicate strong market potential for Apyx's helium plasma technology, which is supported by more than 90 clinical documents.

#APYX Apyx Medical Corporation Announces Launch of Renuvion® in China

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

8 months ago

Apyx Medical, Maker of Renuvion Technology, Announces Q2 2025 Earnings Date and Conference Call Medical technology company Apyx schedules Q2 2025 results with analyst conference call. Learn about latest Renuvion and AYON performance. Get Details

#APYX Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

10 months ago

Renuvion Transforms Real Patients into Runway Models: Miami Swim Week Features Groundbreaking Skin Tightening Results Revolutionary helium plasma technology showcases real patient transformations. See how this FDA-cleared treatment delivers dramatic skin tightening results. Learn more.

#APYX Renuvion® Brings Real Transformations to the Runway at Miami Swim Week

www.stocktitan.net/news/APYX/renuvion-bring...

StockTitan

@stocktitan.net

10 months ago

Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™ Apyx Medical Corporation (NASDAQ:APYX) has received FDA 510(k) clearance for its innovative AYON Body Contouring System™, the first FDA-cleared all-in-one platform for aesthetic surgical procedures. The system integrates multiple functionalities including fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities. AYON incorporates the company's proprietary Renuvion® technology and features advanced LIFT Technology for real-time adjustments. The initial clearance covers various aesthetic treatments including Renuvion for loose skin, ultrasound-assisted liposuction, and electrocoagulation. Apyx plans to expand AYON's capabilities with an additional 510(k) submission for power liposuction later in 2025. The commercial launch is scheduled for the second half of 2025, targeting key opinion leader surgeons in strategic locations. The company aims to capitalize on the growing demand from over 15 million GLP-1 drug users seeking body contouring solutions.

#APYX Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

10 months ago

Apyx Medical Corporation Reports First Quarter 2025 Financial Results Apyx Medical Corporation (NASDAQ:APYX) reported Q1 2025 financial results showing mixed performance. Total revenue decreased 8% to $9.4M compared to $10.2M in Q1 2024. The Advanced Energy segment grew 6% to $7.9M, driven by strong generator sales and U.S. single-use handpiece growth of 14%. However, OEM revenue declined 45% to $1.5M. Net loss improved significantly, decreasing 45% to $4.2M from $7.6M year-over-year. The company is preparing to launch its new AYON™ Body Contouring System in H2 2025, pending FDA clearance. The system integrates multiple functions including Renuvion technology, liposuction, and contouring capabilities. For FY2025, Apyx reaffirmed guidance of $47.6M-$49.0M in total revenue.

#APYX Apyx Medical Corporation Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

11 months ago

Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures Two studies report favorable clinical outcomes and safety data for Renuvion ® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin

#APYX Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

11 months ago

Apyx Medical Sets Q1 Earnings Date: Latest Results Coming for Renuvion Plasma Technology Maker Join Apyx Medical's Q1 earnings call on May 8 at 8 AM ET. Get insights on Renuvion plasma technology performance and management outlook. Access details inside.

#APYX Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

www.stocktitan.net/news/APYX/apyx-medical-c...

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

Small-cap stocks in new downtrend with average directional index, Wed Apr 23rd - #BANL #APYX #XIN #EVH - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

1 year ago

Apyx Medical Cuts Losses in Half, Reduces Workforce 25% in Major Turnaround Push Apyx Medical streamlines operations with 25% workforce reduction, targeting $4.3M savings. Q4 shows 52% lower losses while advancing AYON launch. 2025 revenue projected at $47.6-49M.

#APYX Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

1 year ago

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025 Apyx Medical (NASDAQ: APYX), developer of the proprietary Renuvion helium plasma and radiofrequency technology, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results release for March 13, 2025, before market opening.The company will host a conference call at 8:30 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested parties can join via phone (877-407-9039 for domestic, 201-689-8470 for international) using access code 13751519, or through the company's webcast link and Investor Relations website section.Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as Renuvion in cosmetic surgery and J-Plasma in hospital surgical markets. The company's products are supported by over 90 clinical documents and provide controlled heat tissue treatment.

#APYX Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

1 year ago

Apyx Medical Sees 25% Q4 Growth in Advanced Energy, Plans AYON Body System Launch for 2025 Apyx Medical reports Q4 revenue of $14.1-14.3M with strong Advanced Energy segment growth. Company announces AYON™ Body Contouring System targeting GLP-1 weight loss market.

#APYX Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results

www.stocktitan.net/news/APYX/apyx-medical-c...

StockTitan

@stocktitan.net

1 year ago

Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™ Apyx Medical (NASDAQ:APYX) has submitted a 510(k) premarket notification to the FDA for its AYON Body Contouring System, nearly 90 days ahead of schedule. The system is designed as an all-in-one platform for surgical body contouring procedures.The initial submission includes multiple functionalities: infiltration, dual aspiration for simultaneous users, ultrasound-assisted liposuction, electrocoagulation for excess tissue removal, volume enhancement capabilities, and Renuvion treatment for loose and lax skin. The company plans to expand AYON's indications with an additional 510(k) submission later this year to include power-assisted liposuction.

#APYX Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™

www.stocktitan.net/news/APYX/apyx-medical-c...

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #APYX ) Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

#StockMarket #News

StockTitan

@stocktitan.net

1 year ago

#APYX Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/APYX/apyx-medical-c...

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #APYX ) Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #APYX ) Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #APYX ) Expected US Company Earnings on Friday, November 8th, 2024

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #APYX ) Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024

#StockMarket #News